Evaluating the Levels of Nesfatin-1 and Ghrelin Hormones in Patients with Moderate and Severe Major Depressive Disorders
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Objective The goal of this study was to evaluate the importance of nesfatin-1, acylated and des-acylated ghrelin, which are known as energy regulatory hormones, in patients with moderate and severe major depression disorders (MDD). Methods Thirty patients with a moderate degree of MDD and, 30 with a severe degree of MDD were used as participants in this study. Thirty subjects without depression were enrolled as a control group. The Hamilton Depression Rating Scale was used to classify the patients with MDD. Blood samples were taken after overnight fasting. The plasma nesfatin-1, acylated ghrelin and des-acylated ghrelin levels were measured using a commercially available enzyme-linked immunosorbent assay kit. Results The nesfatin-1, the acylated ghrelin and the des-acylated ghrelin levels were found to be significantly higher in severe MDD (3.92±0.4 ng/mL; 88.56±4.1 pg/mL; 962.76±67 pg/mL) as compared to moderate MDD (2.91±0.5 ng/mL; 77.63±4.19 pg/mL; 631.16± 35 pg/mL), or the control (1.01±0.3 ng/mL; 58.60±9.00 pg/mL; 543.13±62 pg/mL), respectively. Conclusion Although nesfatin-1 and ghrelin are known as adversely affecting the hormones involving the regulation of appetite and food intake, they all increase in depressive patients and are even associated with the severity of the disease. In clinical medicine, the evaluation of the role of nesfatin-1 and ghrelin in endocrine and neu-roendocrine regulation of major metabolic functions is an important key mechanism in solving numerous diseases associated with endocrine and neuroendocrine disturbance. Increased levels of nesfatin-1 and ghrelin may also be important criteria in describing the prognoses of the patients and the effectiveness of the treatments.
Abstract
Objective The goal of this study was to evaluate the importance of nesfatin-1, acylated and des-acylated ghrelin, which are known as energy regulatory hormones, in patients with moderate and severe major depression disorders (MDD). Methods Thirty patients with a moderate degree of MDD and, 30 with a severe degree of MDD were used as participants in this study. Thirty subjects without depression were enrolled as a control group. The Hamilton Depression Rating Scale was used to classify the patients with MDD. Blood samples were taken after overnight fasting. The plasma nesfatin-1, acylated ghrelin and des-acylated ghrelin levels were measured using a commercially available enzyme-linked immunosorbent assay kit. Results The nesfatin-1, the acylated ghrelin and the des-acylated ghrelin levels were found to be significantly higher in severe MDD (3.92±0.4 ng/mL; 88.56±4.1 pg/mL; 962.76±67 pg/mL) as compared to moderate MDD (2.91±0.5 ng/mL; 77.63±4.19 pg/mL; 631.16± 35 pg/mL), or the control (1.01±0.3 ng/mL; 58.60±9.00 pg/mL; 543.13±62 pg/mL), respectively. Conclusion Although nesfatin-1 and ghrelin are known as adversely affecting the hormones involving the regulation of appetite and food intake, they all increase in depressive patients and are even associated with the severity of the disease. In clinical medicine, the evaluation of the role of nesfatin-1 and ghrelin in endocrine and neu-roendocrine regulation of major metabolic functions is an important key mechanism in solving numerous diseases associated with endocrine and neuroendocrine disturbance. Increased levels of nesfatin-1 and ghrelin may also be important criteria in describing the prognoses of the patients and the effectiveness of the treatments.
참고문헌 (38)
- Mischoulon D, "Depression and eating disorders: treatment and course", J Affect Disord, 130, pp.470~477 (2010)
- de Kloet ER, "Stress and the brain: from adaptation to disease", Nat Rev Neurosci, 6, pp.463~475 (2005)[DOI]
- Serova LI, "Blockage of melanocortin-4 receptors by intranasal HS014 attenuates single prolonged stresstriggered changes in several brain regions", J Neurochem, 131, pp.825~835 (2014)[DOI]
- Ari M, "High plasma nesfatin-1 level in patients with major depressive disorder", Prog Neuropsychopharmacol Biol Psychiatry, 35, pp.497~500 (2011)[DOI]
- Bloem B, "Sex-specific differences in the dynamics of cocaine- and amphetamineregulated transcript andnesfatin-1 expressions in the midbrain of depressed suicide victims vs. controls", Neuropharmacology, 62, pp.297~303 (2012)[DOI]
- Ishitobi Y, "Serum ghrelin levels and the effects of antidepressants in major depressive disorder and panic disorder", Neuropsychobiology, 66, pp.185~192 (2012)[DOI]
- Oh-I S, "Identification of nesfatin-1 as a satiety molecule in the hypothalamus", Nature, 443, pp.709~712 (2006)[DOI]
- Yosten GL, "Nesfatin-1 exerts cardiovascular actions in brain: possible interaction with the central melanocortin system", Am J Physiol Regul Integr Comp Physiol, 297, pp.330~336 (2009)[DOI]
- Nonogaki K, "Serotonin systems upregulate the expression of hypothalamic NUCB2 via 5- HT2C receptors and induce anorexia via a leptin independent pathway in mice", Biochem Biophys Res Commun, 372, pp.186~190 (2008)[DOI]
- Yoshida N, "Stressor-responsive central nesfatin-1 activates corticotropin-releasing hormone, noradrenaline and serotonin neurons and evokes hypothalamic-pituitary-adrenal axis", Aging (Albany NY), 2, pp.775~784 (2010)
- Palasz A, "Nesfatin-1, a unique regulatory neuropeptide of the brain", Neuropeptides, 46, pp.105~112 (2012)[DOI]
- Hofmann T, "NUCB2", nesfatin-1 is associated with elevated levels of anxiety in anorexia nervosa, 2015, pp.10, e0132058~
- Kojima M, "Ghrelin is a growth-hormone-releasing acylated peptide from stomach", Nature, 402, pp.656~660 (1999)[DOI]
- Gnanapavan S, "The tissue distribution of the mRNA of ghrelin and subtypes of its receptor, GHS-R, in humans", J Clin Endocrinol Metab, 87, pp.2988~ (2002)[DOI]
- Nakazato M, "A role for ghrelin in the central regulation of feeding", Nature, 409, pp.194~198 (2001)[DOI]
- Chuang JC, "Ghrelin's roles in stress, mood, and anxiety regulation", Int J Pept, 2010, pp.460549~ (2010)
- Jerlhag E, "Requirement of central ghrelin signaling for alcohol reward", Proc Natl Acad Sci USA, 106, pp.11318~11323 (2009)[DOI]
- Andrews ZB, "The extra-hypothalamic actions of ghrelin on neuronal function", Trends Neurosci, 34, pp.31~40 (2011)[DOI]
- Spencer SJ, "Ghrelin's role in the hypothalamic-pituitary-adrenal axis stress response: implications for mood disorders", Biol Psychiatry, 78, pp.19~27 (2015)[DOI]
- Kanehisa M, "Administration of antisense DNA for ghrelin causes an antidepressant and anxiolytic response in rats", Prog Neuropsychopharmacol Biol Psychiatry, 30, pp.1403~1407 (2006)[DOI]
- Lutter M, "The orexigenic hormone ghrelin defends against depressive symptoms of chronic stress", Nat Neurosci, 11, pp.752~753 (2008)[DOI]
- American Psychiatric Association, "Diagnostic and Statistical Manual of Mental Disorders. 4th Edition" (1994), American Psychiatric Press
- Hamilton M, "A rating scale for depression", J Neurol Neurosurg Psychiatry, 23, pp.56~62 (1960)[DOI]
- Emmerzaal TL, "Nesfatin-1; implication in stress and stressassociated anxiety and depression", Curr Pharm Des, 19, pp.6941~6948 (2013)[DOI]
- Labarthe A, "Ghrelin-Derived Peptides: A Link between Appetite", Reward, GH Axis, and Psychiatric Disorders?, 2014, pp.5, 163~
- Brailoiu GC, "Nesfatin-1: distribution and interaction with a G protein-coupled receptor in the rat brain", Endocrinology, 148, pp.5088~5094 (2007)[DOI]
- Xu YY, "Acute, but not chronic, stress increased the plasma concentration and hypothalamic mRNA expression of NUCB2", nesfatin-1 in rats, 2015, pp.54, 47~53
- Barim AO, "Ghrelin, paraoxonase and arylesterase levels in depressive patients before and after citalopram treatment", Clin Biochem, 42, pp.1076~1081 (2009)[DOI]
- Schmid DA, "Changes of sleep architecture, spectral composition of sleep EEG, the nocturnal secretion of cortisol, ACTH, GH, prolactin, melatonin, ghrelin, and leptin, and the DEX-CRH test in depressed patients during treatment with mirtazapine", Neuropsychopharmacology, 31, pp.832~844 (2006)[DOI]
- Kurt E, "The effects of electroconvulsive therapy on ghrelin, leptin and cholesterol levels in patients with mood disorders", Neurosci Lett, 426, pp.49~53 (2007)[DOI]
- Saliha Ozsoy, "Serum Ghrelin and Leptin Levels in Patients with Depression and the Effects of Treatment", PSYCHIATRY INVESTIGATION, 11(2), pp.167~172 (2014), 대한신경정신의학회[DOI]
- Kluge M, "Ghrelin plasma levels are not altered in major depression", Neuropsychobiology, 59, pp.199~204 (2009)[DOI]
- Hansson C, "Central administration of ghrelin alters emotional responses in rats: behavioral, electrophysiological and molecular evidence", Neuroscience, 180, pp.201~211 (2011)[DOI]
- Bayliss JA, "Ghrelin is neuroprotective in Parkinson's disease: molecular mechanisms of metabolic neuroprotection", Ther Adv Endocrinol Metab, 4, pp.25~36 (2013)[DOI]
- Bali A, "An integrative review on role and mechanisms of ghrelin in stress, anxiety and depression", Curr Drug Targets, 17, pp.495~507 (2016)[DOI]
- Stengel A, "Ghrelin, des-acyl ghrelin and nesfatin-1 in gastric X", A-like cells: role as regulators of food intake and body weight, 2010, pp.31, 357~369
- Algul S, "Serum nesfatin-1 levels in patients with different glucose tolerance levels", Physiol Res, 65, pp.979~985 (2016)
- Wittekind DA, "Ghrelin in psychiatric disorders a review", Psychoneuroendocrinology, 52, pp.176~194 (2015)[DOI]